Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging

* INCLUSION CRITERIA In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Participant \>=18 years old 4. Has a specific diagnosis of a cardiopulmonary and/or vascular disease that puts them at risk of developing or having developed tissue fibrosis. 5. Has undergone prior imaging of lungs, heart, and/or vasculature with chest CT 6. Able to lie on the PET/CT scanner for imaging up to 45 minutes. 7. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of FAPI-PET/CT or the FDG PET/CT scan. 8. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study participation and for an additional 4 weeks after the end of FAPI-PET/CT or the FDG PET/CT scan. 9. Ability of subject to understand and the willingness to sign a written informed consent document. EXCLUSION CRITERIA An individual who meets any of the following criteria will be excluded from participation in this study: 1. History of allergic reactions attributed to compounds of similar chemical or biologic composition to 18F-FAPI-74 or other agents used in the study. 2. Uncontrolled intercurrent illness, factors, or social situations that would limit compliance with study requirements 3. Pregnancy or lactation 4. Women able to become pregnant or men actively trying to father a child and are unwilling to use an effective form of birth control during the study and 4 weeks after the last 18F-FAPI-74 PET/CT scan or the FDG PET/CT scan. 5. Subjects with severe claustrophobia unresponsive to oral anxiolytics. 6. Subjects weighing \> 350 lbs (weight limit for PET scanner table), or unable to fit within the imaging gantry